Company Watch

Glenmark to market more generics

Our News Bureau - Mumbai

Glenmark Pharmaceuticals received USFDA approval to market Pravastatin Sodium oral tablets 10 mg, 20 mg and 40 mg. It is a generic version of Bristol Myers Squibb brand Pravachol that has annual sales of over $861 million. Glenmark is manufacturing the finished dose formulation at its USFDA approved manufacturing facility in Goa, India. Glenmark's US subsidiary, Glenmark Pharmaceuticals USA is responsible for marketing the product in the US and will commence supplies of the drug to customers immediately. Glenmark has also received USFDA approval to market Naproxen Sodium oral tablets EQ 250 mg and 500 mg base. It is a generic version of Roche's brand Anaprox and Naproxen oral tablets 250 mg, 375 mg and 500 mg, a generic version of Hoffmann-La Roche AG brand Naprosyn. The drugs have annual sales of $13 million and $53 million respectively. With these approvals, Glenmark's subsidiary GPI will have 15 generic products in the US market. The company has over 35 ANDAs undergoing USFDA approval process/launch.